Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 1,838 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo- C Clear all

Conditions: Type 1 Diabetes, Diabetes Mellitus, Peripheral Diabetic Neuropathy
Interventions: CBX129801, Placebo; Drug
Lead sponsor: Cebix Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Escondido, California • Tustin, California • Walnut Creek, California + 5 more

Conditions: Major Depressive Disorder, Depression
Interventions: Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.; Drug · Device
Lead sponsor: Marta Peciña, MD PhD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Asthma, Pulmonary Function, Wheezing, In Utero Nicotine
Interventions: No active intervention in this protocol (previously randomized to Vitamin C), No active intervention in this protocol (previously randomized to Placebo); Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Years to 16 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Indianapolis, Indiana • Portland, Oregon

Conditions: Chronic Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo; Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: Smoking Cessation
Interventions: SBP-9330, Placebo; Drug
Lead sponsor: Camino Pharma, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 87
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor 25 mg/75 mg, Ivacaftor 75 mg/150 mg, Ivacaftor 150 mg or 250 mg, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more

Conditions: Shigella Infection
Interventions: Placebo, WRSs2, WRSs3; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus Type 2
Interventions: PF-07081532, Placebo, Clopidogrel; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0); Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more

Conditions: Healthy
Interventions: T89 Group A, Placebo Group A, Placebo Group B, T89 Group B, Placebo Group C, T89 Group C; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hepatitis C, Chronic
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more

Conditions: Influenza
Interventions: IN Placebo, IM Placebo, BPL-1357; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Smallpox
Interventions: Live vaccinia virus vaccine, MVA Smallpox Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: Clostridium Difficile Infection
Interventions: Placebo, CRS3123; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acromegaly
Interventions: IONIS-GHR-LRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 7
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 3 more

Conditions: Fontan Procedure, Hypoplastic Left Heart Syndrome, Tricuspid Atresia
Interventions: Vitamin C, Placebo; Dietary Supplement
Lead sponsor: University of Michigan; Other
Eligibility: 8 Years to 25 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions: TD-9855, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 40 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more

Conditions: Bacterial Infections
Interventions: Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sleep Apnea Syndromes
Interventions: Antioxidant cocktail; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years to 40 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy Volunteer
Interventions: A-005, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 4 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Oleclumab, Monalizumab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,051 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 33
States / cities: San Diego, California • New Haven, Connecticut • Stuart, Florida + 28 more

Search by objective public record fields.

Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

A First-in-Human Study of SBP-9330 in Healthy Subjects

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

MVA Post-Event: Administration Timing and Boost Study

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Respiratory and Autonomic Plasticity Following Intermittent Hypoxia

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer